Contact

New York Office
800 Third Avenue, 21st Floor
New York, NY 10022

Tel: 212-660-7250

Email: eric.zitter@achelous.com

  • January 2023
    has been acquired by
    The undersigned acted as financial advisor to Alcedis, GmbH
  • November 2022
    has been acquired by
    The undersigned acted as financial advisor to Expression Systems, LLC
  • October 2022
    has been acquired by
    The undersigned acted as financial advisor to AQW Holdings, Inc. d.b.a. Qfix
  • August 2022
    has been acquired by
    The undersigned acted as financial advisor to AusDiagnostics
  • July 2022
    has been acquired by
    The undersigned acted as financial advisor to Cergentis B.V.
  • July 2022
    has been acquired by
    The undersigned acted as financial advisor to proderm GmbH
  • June 2022
    has been acquired by
    The undersigned acted as financial advisor to SAI MedPartners
  • February 2022
    has acquired
    The undersigned acted as financial advisor to TCP Analytical
  • November 2021
    has been acquired by
    The undersigned acted as financial advisor to Regulatory Compliance Associates Inc.
  • August 2021
    has been acquired by
    The undersigned acted as financial advisor to DRG International Inc.
  • August 2021
    has been acquired by
    The undersigned acted as financial advisor to bioskin GmbH
  • July 2021
    has been acquired by
    The undersigned acted as financial advisor to nanoComposix Holdings, Inc.
  • May 2021
    has been acquired by
    The undersigned acted as financial advisor to Clinical Outcomes Solutions
  • March 2021
    has been acquired by
    The undersigned acted as financial advisor to Diamond Pharma Services
  • February 2021
    has been acquired by
    The undersigned acted as financial advisor to Delphi Genetics
  • October 2020
    has been acquired by
    The undersigned acted as financial advisor to MD Biosciences, Inc.
  • September 2020
    has been acquired by
    The undersigned acted as financial advisor to American Laboratory Products Company, Ltd.
  • September 2020
    has been acquired by
    The undersigned acted as financial advisor to Maetrics LLC
  • August 2020
    has been acquired by
    The undersigned acted as financial advisor to CTK Biotech, Inc.
  • February 2020
    has been acquired by
    The undersigned acted as financial advisor to BresMed Health Solutions Ltd
  • January 2020
    has been acquired by
    The undersigned acted as financial advisor to Statistics Collaborative, Inc.
  • December 2019
    has been acquired by
    The undersigned acted as financial advisor to MLM Medical Labs GmbH
  • October 2019
    has been acquired by
    The undersigned acted as financial advisor to Specialized Medical Services-oncology BV
  • July 2019
    has been acquired by
    The undersigned acted as financial advisor to Eurolyser Diagnostica GmbH
  • July 2019
    has acquired
    The undersigned acted as financial advisor to LifeSpan BioSciences
  • March 2019
    has been acquired by
    The undersigned acted as financial advisor to Quorum Review, Inc.
  • January 2019
    has been acquired by
    The undersigned acted as financial advisor to ProductLife Group
  • January 2019
    has been acquired by
    The undersigned acted as financial advisor to CoreBiome, Inc.
  • October 2018
    has been acquired by
    The undersigned acted as financial advisor to Pennside Partners Ltd.
  • September 2018
    has been acquired by
    The undersigned acted as financial advisor to NovaTec Immundiagnostica GmbH
  • September 2018
    has acquired
    The undersigned acted as financial advisor to Thompson Street Capital Partners
  • September 2018
    has been acquired by
    The undersigned served as financial advisor to HyTest Ltd.
  • July 2018
    has been acquired by
    The undersigned served as financial advisor to Gold Standard Diagnostics Corp.
  • May 2018
    has been acquired by
    The undersigned served as financial advisor to Biovian Oy
  • January 2018
    has been acquired by
    The undersigned served as financial advisor to LifeCodexx AG
  • June 2017
    has been acquired by
    The undersigned acted as financial advisor to Coté Orphan, LLC
  • May 2017
    has been acquired by
    The undersigned acted as financial advisor to PharmaCell B.V.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Emergo Group, Inc.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Calbiotech, Inc.
  • January 2017
    has been acquired by
    The undersigned acted as financial advisor to BioControl Systems, Inc.
  • August 2016
    has been acquired by
    The undersigned acted as financial advisor to SPEware Corporation
  • July 2016
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • June 2016
    has been acquired by
    The undersigned acted as financial advisor to Cisbio Bioassays
  • December 2015
    has acquired
    The undersigned acted as financial advisor to Abzena plc
  • December 2015
    has acquired
    The undersigned acted as financial adviser to Sharps Compliance Corp.
  • October 2015
    has been acquired by
    The undersigned acted as financial advisor to Kinesis Pharma BV
  • August 2015
    has been acquired by
    The undersigned acted as financial advisor to DIAsource ImmunoAssays SA
  • July 2015
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • March 2015
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • July 2014
    has been acquired by
    The undersigned acted as financial advisor to IBL International Holding BV
  • July 2014
    has been acquired by
    The undersigned served as financial advisor to Phlexglobal Limited
  • June 2014
    has been acquired by
    The undersigned served as financial advisors to Pharmalink Consulting
  • December 2013
    has acquired assets from
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • August 2013
    has been acquired by
    The undersigned acted as financial advisor to Kirkegaard & Perry Laboratories Inc
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to The Anson Group LLC
  • July 2013
    has signed a definitive agreement to sell its orthopedic implant assets and business to
    an Apax Partners company The undersigned acted as financial advisor to Austofix Group Limited
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to Kreatech Holding B.V.
  • July 2013
    has been acquired by
    USD$10,000,000
    The undersigned acted as financial advisor to Matrical Bioscience Inc
  • May 2013
    has been acquired by
    The undersigned acted as advisor to Triangle Biomedical Sciences Inc.
  • August 2012
    has been acquired by
    The undersigned acted as advisor to JSW Life Sciences GmbH
  • March 2012
    has acquired assets from
    US$164M plus up to US$20M in milestones
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • December 2011
    invests in
    The undersigned acted as advisor to Ansell Limited for the investment
  • August 2010
    has been acquired by
    The undersigned acted as financial advisor to EnviroLogix, Inc.
  • March 2010
    has been acquired by
    USD$59,000,000
    The undersigned acted as financial advisor to Finnzymes Oy
  • December 2009
    has licensed its ReGet® drug delivery system for ophthalmic indications to
    The undersigned acted as financial advisor to BTG olc
  • October 2009
    has been acquired by
    The undersigned acted as financial advisor to Anaspec Inc.
  • August 2009
    has sold its HySolv™ drug delivery technology to
    The undersigned acted as financial advisor to BTG plc
  • January 2009
    has been acquired by
    The undersigned acted as financial advisor to the shareholders of Labcoat Limited
  • December 2008
    has acquired
    The undersigned is acting as financial advisor to Biocompatibles International
  • December 2008
    has acquired
    The undersigned rendered a Fairness Opinion to Affymetrix, Inc.
  • February 2008
    has been acquired by
    The undersigned is acting as financial advisor to Sigma Pharmaceuticals
  • January 2008
    has been acquired by
    The undersigned is acting as financial advisor to Panbio Limited
  • May 2007
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • March 2007
    has sold its Human Health point-of-care diagnostic products business to
    The undersigned acted as financial advisor to Agenix Limited
  • February 2007
    Strategic alliance and investment of up to £32,100,000 in
    The undersigned acted as financial advisor to GeneMedix, PLC
  • December 2006
    Announced M&A advisory and restructuring
    The undersigned acted as financial advisor to Panbio Limited
  • December 2006
    has acquired
    The undersigned acted financial advisor to Novozymes A/S
  • August 2006
    has acquired
    The undersigned acted as financial advisor to Meditech Research Limited
  • July 2006
    has acquired Delta Biotechnology Ltd from
    The undersigned acted as financial advisor to Novozymes A/S
  • April 2006
    has assigned IP and granted distribution rights for its Animal Health business to
    The undersigned acted as financial advisor to Agenix Limited
  • October 2005
    M&A advisory and valuation analysis
    The undersigned acted as financial advisor to CogState Limited
  • September 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to Genetic Technologies Limited
  • June 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to ChemGenex Pharmarceuticals Limited
  • January 2005
    awarded to
    for its investment banking role in the creation of
  • December 2004
    has been acquired by
    The undersigned acted as financial advisor to AGT Biosciences Ltd.
© 2023 Achelous Partners. 800 Third Avenue, 21st Floor, New York, NY 10022   /   Tel: 212.660.7250   /   Fax: 917.475.9457   /   Privacy Policy   /   site by cleverdesign